GRF6019

About Alkahest

Alkahest, a Grifols subsidiary founded in 2014, is a biotechnology company pioneering a novel approach to drug discovery by analyzing the plasma proteome to identify proteins that promote health or drive disease. Its proprietary platform integrates AI and multiomics with access to Grifols' vast biorepository of over 100 million plasma samples, enabling the discovery of both therapeutic candidates and biomarkers. The company's pipeline includes clinical-stage programs targeting neurodegenerative diseases like Alzheimer's and Parkinson's, as well as age-related conditions such as wet AMD, positioning it at the intersection of plasma science and precision medicine.

About Alkahest

Alkahest, a Grifols subsidiary founded in 2014, is a biotechnology company pioneering a novel approach to drug discovery by analyzing the plasma proteome to identify proteins that promote health or drive disease. Its proprietary platform integrates AI and multiomics with access to Grifols' vast biorepository of over 100 million plasma samples, enabling the discovery of both therapeutic candidates and biomarkers. The company's pipeline includes clinical-stage programs targeting neurodegenerative diseases like Alzheimer's and Parkinson's, as well as age-related conditions such as wet AMD, positioning it at the intersection of plasma science and precision medicine.

Therapeutic Areas